Double-Stranded DNA (dsDNA) Antibodies, IgG, Serum
Use
The test is useful for evaluating patients with clinical features or at-risk for systemic lupus erythematosus (SLE) and for monitoring disease activity in patients with SLE previously positive for double-stranded DNA IgG antibodies. It detects antibodies to double-stranded DNA (dsDNA), a specific marker for SLE, and aids in the assessment of disease activity. Positive results suggest SLE in the appropriate clinical context, though their performance is subject to the methodological and clinical factors.
Special Instructions
Test is available for order by NY State clients, and requires serum as specimen. Additional tests may be added based on reflex criteria outlined in testing algorithms. Forms such as the Kidney Transplant Test Request or General Request form should accompany specimens if not ordered electronically.
Limitations
Measurements of IgG antibodies to dsDNA are semiquantitative. Variability in test reactivity can occur, and slight changes should not be solely used to anticipate clinical disease course changes. False-positives are typically low titer, and the test alone should not guide treatment decisions. Negative results do not preclude SLE diagnosis, as not all SLE patients have these antibodies detectable at all times.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 33799-8
- 33799-8
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.3 mL
Minimum Volume
See Specimen Required
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis: OK, Gross lipemia: OK, Gross icterus: OK
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |